Treatment and course of community-acquired pneumonia caused by atypical pathogens;Neumonía adquirida en la comunidad por gérmenes atípicos: Tratamiento y evolución

Archivos de Bronconeumologia

Volumn 42, Issue 9, 2006, Pages 430-433

  Fernández Álvarez, Ramón ^a,b   Suárez Toste, Isabel ^a   Rubinos Cuadrado, Gemma ^a   Medina Gonzálvez, Agustín ^a   Gullón Blanco, José Antonio ^a   González Martín, Isidro ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b NONE   (Spain)

Author keywords

Antibiotic treatment for pneumonia; Atypical pneumonia; Community acquired pneumonia

Indexed keywords

MACROLIDE; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; COXIELLA BURNETII; DISEASE COURSE; FEMALE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LEGIONELLA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOPLASMA PNEUMONIAE; PATHOGENICITY; TREATMENT OUTCOME;

EID: 33750338277     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13092412     Document Type: Article

References (22)

1. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2001;163:1730-54.
2. Dorca J, Bello S, Blanquer J, De Cellis R, Molinos L, Torres A, et al. Diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Arch Bronconeumol. 1997;33:240-6.
3. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax. 2001;56 Suppl IV;1-64.
4. Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT). Actualización de las recomendaciones ALAT sobre la neumonía adquirida en la comunidad. Arch Bronconeumol. 2004;40:364-74.
5. Örtqvist A. Treatment of community-acquired lower respiratory tract infections in adults. Eur Respir J. 2002;36 Suppl:40-53.
6. Molinos L. Importancia de la etiología polimicrobiana en la neumonía. Arch Bronconeumol. 2003;39 Supl:22-6.
7. File TM, Garau J, Blasi F, Chidiac C, Klusman K, Code H, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest. 2004;125:1888-901.
8. Fine MJ, Auble TE, Yealy D, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
9. Marrie TJ. Deaths in risk classes I-III: a measure of quality of care in patients hospitalised with CAP? Eur Respir J. 2004;23:103-5.
10. Stahl JA, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Inter Med. 1999;159:2576-80.
11. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999;159:2562-72.
12. Fernández R, Gullón JA, Rubinos G, Jiménez A, Medina A, Hernández C, et al. Neumonía adquirida en la comunidad: influencia de la duración de la antibioterapia intravenosa en la estancia hospitalaria y relación coste/efectividad. Arch Bronconeumol. 2001;37:366-70.
13. Capelastegui A, España PP, Quintana JM, Gorordo I, Martínez Urquiri A, Idoiaga I, et al. Pacientes ingresados por neumonía adquirida en la comunidad: estudio comparativo en función de la especialidad del servicio médico responsable. Arch Bronconeumol. 2005;41:300-6.
14. Menéndez R, Torres A. Neumonía: predecir la mala evolución. Arch Bronconeumol. 2005;41:475-7.
15. Mundy LM, Oldach D, Auwaerter PG, Gaydos CA, Moore RD, Bartlett JG, et al. Implications for macrolide treatment in community-acquired pneumonia. Chest. 1998;113:1201-6.
16. Barton K, Nicholls DP, Stanford CF, Connolly JH, Wilson TS. Which atypical pneumonia? J Infect. 1989;19:294-7.
17. Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest. 2004;125 Suppl:70-8.
18. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004;170:440-4.
19. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J. 2002;20 Suppl 36:20-7.
20. Mills GD, Oehley MR, Arrol B. Effectiveness of beta-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ. 2005;330:456-62.
21. Garau J. Role of beta-lactam agents in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2005;24:83-99.
22. Grupo de Estudio de la Neumonía Adquirida en la Comunidad. Área de Tuberculosis e Infecciones Respiratorias (TIR). Normativa para el diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Arch Bronconeumol. 2005;41:272-89.